Galectin Therapeutics Valuation
| GALT Stock | USD 2.84 0.07 2.53% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Galectin Therapeutics retains a regular Real Value of $4.75 per share. The prevalent price of the firm is $2.84. Our model calculates the value of Galectin Therapeutics from evaluating the firm fundamentals such as Return On Asset of -1.04, return on equity of -37.28, and Shares Owned By Insiders of 30.95 % as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Galectin Therapeutics' valuation include:
Price Book 207.6975 | Enterprise Value 257.7 M | Enterprise Value Ebitda (4.04) |
Undervalued
Today
Please note that Galectin Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Galectin Therapeutics is based on 3 months time horizon. Increasing Galectin Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Galectin Therapeutics' intrinsic value may or may not be the same as its current market price of 2.84, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.84 | Real 4.75 | Target 11.0 | Hype 2.82 | Naive 2.7 |
The intrinsic value of Galectin Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Galectin Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Galectin Therapeutics helps investors to forecast how Galectin stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Galectin Therapeutics more accurately as focusing exclusively on Galectin Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Galectin Therapeutics' intrinsic value based on its ongoing forecasts of Galectin Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Galectin Therapeutics' closest peers.
Galectin Therapeutics Cash |
|
Galectin Valuation Trend
Galectin Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Galectin Therapeutics' financial worth over time. Using both Galectin Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Galectin Therapeutics Total Value Analysis
Galectin Therapeutics is currently expected to have valuation of 257.68 M with market capitalization of 177.93 M, debt of 71.81 M, and cash on hands of 15.83 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Galectin Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
257.68 M | 177.93 M | 71.81 M | 15.83 M |
Galectin Therapeutics Asset Utilization
One of the ways to look at asset utilization of Galectin is to check how much profit was generated for every dollar of assets it reports. Galectin Therapeutics retains a negative application of resources of -1.04 (percent), losing $0.0104 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Galectin Therapeutics shows how discouraging it operates for each dollar spent on its resources.Galectin Therapeutics Ownership Allocation
Galectin Therapeutics has a total of 62.76 Million outstanding shares. Galectin Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Galectin Therapeutics Profitability Analysis
Net Loss for the year was (41.07 M) with profit before overhead, payroll, taxes, and interest of 0.About Galectin Therapeutics Valuation
The stock valuation mechanism determines Galectin Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Galectin Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Galectin Therapeutics. We calculate exposure to Galectin Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Galectin Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -33 K | -34.6 K |
Galectin Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Galectin Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 60.2 M |
Galectin Therapeutics Current Valuation Indicators
Galectin Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Galectin Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Galectin Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Galectin Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Galectin Therapeutics' worth.Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.